Cleared Traditional

K200584 - xPORT 304 (miCOR) System Lens Fragmenta...

K200584 is an FDA 510(k) clearance for xPORT 304 (miCOR) System Lens Fragmenta..., manufactured by Carl Zeiss Meditec Cataract Technology, Inc.. The device is a Class 2 Ophthalmic device with product code HQC cleared through the Traditional 510(k) pathway after a 147-day FDA review.

K200584 · Carl Zeiss Meditec Cataract Technology, Inc. · Ophthalmic device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 2020
Decision
147d
Days
Class 2
Risk

K200584 is an FDA 510(k) clearance for the xPORT 304 (miCOR) System Lens Fragmentation System. Classified as Unit, Phacofragmentation (product code HQC), Class II - Special Controls.

Submitted by Carl Zeiss Meditec Cataract Technology, Inc. (Reno, US). The FDA issued a Cleared decision on July 31, 2020 after a review of 147 days - within the typical 510(k) review window.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.4670 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Ophthalmic review framework, consistent with the majority of Class II 510(k) submissions.

View all Carl Zeiss Meditec Cataract Technology, Inc. devices

FDA 510(k) Submission Details - K200584

510(k) Number K200584 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 06, 2020
Decision Date July 31, 2020
Days to Decision 147 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
37d slower than avg
Panel avg: 110d · This submission: 147d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

HQC Device Classification - Class 2, Special Controls

Product Code HQC Unit, Phacofragmentation
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 886.4670
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Ophthalmic devices follow this clearance model.

Regulatory Peers - HQC Unit, Phacofragmentation

All 121
Devices cleared under the same product code (HQC) and FDA review panel - the closest regulatory comparables to K200584.
QUATERA 700
K212241 · Carl Zeiss Meditec, AG · Apr 2022
VERITAS Phacoemulsification Console, VERITAS Advanced Fluidics Pack and Advanced Infusion Pack, VERITAS Swivel Handpiece, VERITAS Advanced Foot Pedal, VERITAS Remote Control
K203060 · Johnson & Johnson Surgical Vision, Inc. · Mar 2021
xPORT S Lens Fragmentation System
K200207 · Carl Zeiss Meditec Cataract Technology, Inc. · Oct 2020
Visalis V500, Visalis S500
K193376 · Carl Zeiss Meditec, AG · Jun 2020
Phacoemulsification Needle (Tip) and Irrigation Sleeve
K192418 · Raico, LLC · May 2020
LEGION System
K191650 · Alcon Research, LLC · Nov 2019